Salt Selection in Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Salt Selection in Drug Development
The selection of an appropriate salt form for a potential drug candidate is an opportunity to modulate its characteristics to improve bioavailability, stability, manufacturability, and patient compliance.


Pharmaceutical Technology
Volume 3, Issue 32

38. USP, USP 29–NF 24 (US Pharmacopeial Convention, Rockville, MD, 2006).

39. K.R. Morris et al., "An Integrated Approach to the Selection of Optimal Salt Form for a New Drug Candidate," Int. J. Pharm. 105 (3), 209–217 (1994).

40. R. Teraoka, M. Otsuka, and Y. Matsuda, "Effects of Temperature and Relative Humidity on the Solid-State Chemical Stability of Ranitidine Hydrochloride," J. Pharm. Sci. 82 (6), 601–604 (1993).

41. H.Y. Ando and G.W. Radebaugh, "Preformulation," in Remington: The Science and Practice of Pharmacy, II, A.R. Gennaro, Ed. (Lippincott Williams and Wilkins, Baltimore, MD, 20th ed., 2002), pp. 700–720.

42. J.F. Remenar et al., "Salt Selection and Simultaneous Polymorphism Assessment via High-Throughput Crystallization: The Case of Sertraline," Org. Proc. Res. Dev. 7 (6), 990–996 (2003).

43. C.R. Gardner, C.T. Walsh, and . Almarsson, "Drugs as Materials: Valuing Physical Form in Drug Discovery," Nat. Rev. Drug. Discov. 3 (11), 926–934 (2004).

44. "Ophthalmic/Otic Dosage Forms," http://www.cop.ufl.edu/safezone/prokai/pha5100/eye.htm, accessed Dec. 20, 2006.

45. Solvias, "Introduction: Solid-State Development," http://www.solvias.com/documents/Dokumente/Downloads_news/Solvias_Salt_and_Polymorphism_Programs.pdf, accessed Dec. 30, 2006.

46. European Agency for the Evaluation of Medicinal Products, "Note for Guidance on the Investigation of Bioavailability and Bioequivalence" (EMEA, London, UK, 2001).

47. FDA, Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations (FDA, Rockville, MD, 2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here